Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer

Table 2

CTC test data before neoadjuvant therapy (baseline).

T Stage	CTC > 0	Median of CTC	Mean of CTC	Positive rate of mesenchymal CTC
2–3(30)	96.7%(29/30)	111	13.2	46.7%(14/30)
4(15)	93.3%(14/15)	88	10.9	60.0%(9/15)
Total (n = 45)	95.6%	110	12.4	51.5%